Colloquium will unify knowledge about mental health across disciplines
The first-ever Yale Mental Health Colloquium will bring together leading scholars in the fields of architecture, business, economics, education, law, neuroscience, psychiatry, public health, social work, and technology for a half-day conversation on the topic.
Yale doctor on CT’s positivity rate nearing 5%, latest research on Moderna’s vaccine, unvaccinated discouraged from Labor Day travel
Yale Infectious Disease expert, Dr. Onyema Ogbuagu discusses CT’s positivity rate nearing 5%, latest research on Moderna’s vaccine, unvaccinated discouraged from Labor Day travelSource: WTNH
New Clinical Trial Evaluates Cardiovascular Outcomes in Tricuspid Valve Repair Without Open Heart Surgery
Investigators at the Yale School of Medicine are participating in an international study to evaluate the clinical outcomes of TriClip, the first non-surgical minimally invasive tricuspid valve repair device developed by Abbott.
Herold is New Chair of International Diabetes Consortium
Kevan C. Herold, MD, C.N.H. Long Professor of Immunobiology and professor of medicine (endocrinology) at Yale School of Medicine, has been named chair of Type 1 Diabetes (T1D) TrialNet, an international consortium dedicated to finding ways to prevent, delay, and slow progression of the disease.
Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy
A new analysis of the EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), found at 30 weeks improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo.Source: DAIC